Sacubitril
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Sacubitril: From Heart Failure to Diabetic Nephropathy
One-Sentence Summary
Sacubitril is a neprilysin inhibitor that is only used clinically in fixed combination with valsartan (sacubitril/valsartan, LCZ696/Entresto) for heart failure with reduced ejection fraction (HFrEF). The TxGNN model predicts the combination may also benefit Diabetic Nephropathy, supported by 2 clinical trials (including one dedicated Phase 4 RCT) and 20 publications, including a secondary analysis of the pivotal PARADIGM-HF trial.
Note: This evidence pack contains 5 TxGNN-predicted indications for sacubitril. Diabetic nephropathy (rank 3) is the only one with any supporting clinical or mechanistic evidence — the other four (brain small vessel disease, HANAC syndrome, rheumatoid arthritis, hemoglobinopathy) have no clinical trials, no relevant literature, and no plausible mechanistic link, and are explicitly scored L5 / Hold. This report therefore focuses on diabetic nephropathy as the only actionable candidate; the remaining four are summarized briefly at the end.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Heart failure with reduced ejection fraction (HFrEF), as part of the sacubitril/valsartan combination — inferred from trial/literature context; not present as structured data in this evidence pack |
| Predicted New Indication | Diabetic Nephropathy |
| TxGNN Prediction Score | 99.50% |
| Evidence Level | L3 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold (flagged internally as "Research Question") |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form (original_moa: [Data Gap]). Based on the trial and literature context in this pack, sacubitril is a prodrug that inhibits neprilysin, raising circulating levels of natriuretic peptides (ANP, BNP), and is co-administered with valsartan (an ARB) to simultaneously block the renin-angiotensin-aldosterone system (RAAS) — the combination is marketed as LCZ696/Entresto for HFrEF.
Heart failure and diabetic nephropathy share substantial pathophysiological overlap: both involve RAAS activation, glomerular/systemic hemodynamic stress, and chronic low-grade inflammation, and the two patient populations frequently overlap clinically (diabetic patients with HFrEF are a common comorbid group). Multiple preclinical studies (rat and mouse models of diabetic kidney disease) show sacubitril/valsartan reduces glomerular hypertension, oxidative stress, and NF-κB/NLRP3-mediated inflammation, and a secondary analysis of the PARADIGM-HF trial (PMID 29661699) found neprilysin inhibition was associated with slower renal function decline in patients with type 2 diabetes already on maximal RAAS blockade — providing translational, human-level support for the mechanistic hypothesis.
Importantly, sacubitril has never been studied or approved as a monotherapy for kidney disease — all supporting evidence relates to the fixed-dose combination with valsartan, not sacubitril alone.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06501651 | Phase 4 | Not yet recruiting | 297 | Randomized, controlled, multicenter "Hyper-Save" study comparing sacubitril/valsartan vs. valsartan alone in patients with mild-to-moderate essential hypertension and type 2 diabetic nephropathy over 12 weeks; primary purpose-designed for this indication, but no results yet. |
| NCT04735354 | N/A | Completed | 268 | Real-world retrospective EMR study of sacubitril/valsartan prescribing in HFrEF patients in India; not designed for diabetic nephropathy specifically, but the HFrEF population likely includes diabetic nephropathy comorbidity — indirect evidence only. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29661699 | 2018 | RCT (secondary analysis) | Lancet Diabetes Endocrinol | Secondary analysis of PARADIGM-HF: neprilysin inhibition slowed renal function decline in type 2 diabetic HF patients already on maximal RAAS blockade. |
| 37549515 | 2023 | Clinical study | Int Immunopharmacol | 112 diabetic nephropathy + hypertension patients; nifedipine + sacubitril/valsartan improved renal function vs. nifedipine + valsartan alone. |
| 40416927 | 2025 | Clinical study | Diabetes Metab Syndr Obes | BOLD-MRI study evaluating renal protective effects of sacubitril/valsartan in type 2 diabetics. |
| 37625003 | 2023 | Review | Diabetes Care | Update on pharmacological pillars slowing diabetic kidney disease progression, including RAAS/neprilysin pathways. |
| 34431635 | 2021 | Review | Revue Médicale Suisse | Discusses potential role of sacubitril/valsartan in type 2 diabetes, including glycemic and renal effects. |
| 30909895 | 2019 | Preclinical (Zucker Obese rat) | Cardiovasc Diabetol | Sacubitril + valsartan combination reduced glomerular and tubular injury more effectively than valsartan alone. |
| 35992034 | 2022 | Preclinical (rat) | Diabetes Metab Syndr Obes | Sacubitril/valsartan improved early diabetic nephropathy via inhibition of the NLRP3 inflammasome pathway. |
| 32596035 | 2020 | Preclinical (rat) | PeerJ | LCZ696 mitigated diabetic nephropathy via reduced oxidative stress, NF-κB inflammation, and glomerulosclerosis. |
| 33870733 | 2021 | Preclinical (db/db & KKAy mice) | Am J Physiol Renal Physiol | Sacubitril/valsartan showed differential renoprotective effects vs. valsartan alone in two diabetic mouse models. |
| 27129187 | 2016 | Preclinical (diabetic rat) | Clin Sci (Lond) | AT1 receptor-neprilysin inhibition produced blood-pressure-independent renoprotection vs. ARB alone. |
Germany / Taiwan Market Information
Sacubitril is not currently marketed in this jurisdiction (market_status: 未上市), and no drug licenses are on file (0 authorizations). No product/authorization table is available.
Safety Considerations
Please refer to the package insert for safety information. No structured key warnings, contraindications, or drug-drug interaction data are currently available for sacubitril in this evidence pack (all fields returned [Data Gap] or not_found).
Other TxGNN Predictions (Screened, Not Pursued)
The remaining 4 predictions in this evidence pack (all rank 5000+, score ~99–99.6%) have no clinical trials, no relevant literature, and no plausible mechanistic link to sacubitril's pharmacology. All are scored L5 / Hold:
| Rank | Predicted Indication | Score | Reason for Hold |
|---|---|---|---|
| 1 | Brain small vessel disease 1 with ocular anomalies | 99.58% | COL4A1-related genetic disorder; no known link to neprilysin/natriuretic peptide pathway |
| 2 | HANAC syndrome (familial hematuria-retinal arteriolar tortuosity) | 99.57% | COL4A1 mutation disorder; no supporting trials or literature |
| 4 | Rheumatoid arthritis | 99.35% | No supporting trials or literature despite theoretical anti-inflammatory rationale |
| 5 | Hemoglobinopathy | 99.18% | No supporting trials, literature, or mechanistic rationale |
These are model artifacts of a high-recall prediction system and should not be pursued without independent mechanistic or clinical signal.
Conclusion and Next Steps
Decision: Hold
Rationale: Diabetic nephropathy has the strongest evidentiary support among all TxGNN predictions for sacubitril, including a purpose-built Phase 4 RCT (not yet recruiting) and a positive secondary analysis of PARADIGM-HF. However, no completed trial has yet demonstrated efficacy for this indication in humans, and sacubitril itself is not marketed in this jurisdiction — this remains a research question, not a near-term repurposing opportunity.
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently a Blocking data gap (DG001)
- Formal MOA and original indication documentation from DrugBank — currently a High severity data gap (DG002)
- Results from NCT06501651 (Hyper-Save study) once recruitment completes
- Confirmation that any future indication claim applies to the sacubitril/valsartan combination, not sacubitril monotherapy
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.